Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
1000
Trial Sponsor
Clinical Trial Start Date
2013
0Primary Completion Date
2018
0Study Completion Date
2018
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Intervention Name
ITCA 650 (exenatide in DUROS)0
Interventional Trial Phase
Phase 30
Participating Facility
Official Name
An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c0
Last Updated
March 7, 2019
0Allocation Type
NA0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0
Study summary
An 39-week plus extensions, open-label study to estimate the reduction in HbA1c in patients with initial HbA1c \>10% \</=12% who are treated with ITCA 650 20 mcg/day for 13 weeks followed by ITCA 650 60 mcg/day for 26 weeks plus optional 26-week extensions with continued treatment with ITCA 650 60 mcg/day
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
